{"title":"Mortality Trends of Biliary Tract Cancers in the United States, 1999-2023: a CDC-WONDER Analysis.","authors":"Jianguo Chen, Guangwei Yang, Xiaodong Sun","doi":"10.1007/s12029-026-01537-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancers (BTCs) comprise a heterogeneous group of malignancies, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, ampulla of Vater tumors, and other or unspecified BTCs. We examined population-level BTC mortality trends and disparities in the US from 1999 to 2023.</p><p><strong>Methods: </strong>Deaths among adults aged ≥ 35 years were obtained from CDC WONDER using ICD-10 codes C22.1, C23, C24.0, C24.1, C24.8, and C24.9. AAMRs per 100,000 were calculated and assessed using Joinpoint regression, with stratification by sex, race/ethnicity, age, census region, and urbanization level. Urbanization analyses used standardized data through 2020.</p><p><strong>Results: </strong>From 1999 to 2023, 226,056 BTC deaths were recorded. Annual deaths increased from 6,121 to 13,637, and the AAMR increased from 4.37 to 6.10 per 100,000 (AAPC, 2.22%; 95% CI, 1.95%-2.50%; P < 0.001), with acceleration after 2007. The Non-Hispanic Black population exhibited the fastest increase in mortality among racial/ethnic groups, with an AAPC of 3.20%, whereas Hispanics had the highest AAMR in 2023. The 35-44-year age group showed the fastest increase despite low mortality (AAPC, 3.77%). In 2023, the Midwest had the highest AAMR, at 5.50 per 100,000, followed by the West at 5.32 per 100,000. In standardized urbanization-stratified data through 2020, metropolitan areas had a higher AAMR than nonmetropolitan areas (4.65 vs. 4.30 per 100,000). Subtype-specific analyses showed that intrahepatic cholangiocarcinoma accounted for the largest proportion of deaths (132,830; 58.76%) and had an increasing AAMR from 1.82 to 4.17 per 100,000, whereas gallbladder cancer accounted for 51,720 deaths (22.88%) and had a declining AAMR from 1.46 to 0.98 per 100,000. Extrahepatic bile duct cancer, ampulla of Vater cancer, and other/unspecified BTCs contributed 18,669, 5,135, and 17,702 deaths, respectively, highlighting that pooled BTC estimates may mask divergent subtype patterns. These opposite iCCA and GBC patterns supported separate subtype reporting rather than interpretation of the pooled BTC estimate alone in this study.</p><p><strong>Conclusions: </strong>BTC mortality among US adults aged ≥ 35 years increased from 1999 to 2023, with demographic, geographic, urbanization-related, and subtype-specific heterogeneity. These findings support subtype-aware surveillance, early detection, and equitable resource allocation.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"57 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-026-01537-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Biliary tract cancers (BTCs) comprise a heterogeneous group of malignancies, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, ampulla of Vater tumors, and other or unspecified BTCs. We examined population-level BTC mortality trends and disparities in the US from 1999 to 2023.
Methods: Deaths among adults aged ≥ 35 years were obtained from CDC WONDER using ICD-10 codes C22.1, C23, C24.0, C24.1, C24.8, and C24.9. AAMRs per 100,000 were calculated and assessed using Joinpoint regression, with stratification by sex, race/ethnicity, age, census region, and urbanization level. Urbanization analyses used standardized data through 2020.
Results: From 1999 to 2023, 226,056 BTC deaths were recorded. Annual deaths increased from 6,121 to 13,637, and the AAMR increased from 4.37 to 6.10 per 100,000 (AAPC, 2.22%; 95% CI, 1.95%-2.50%; P < 0.001), with acceleration after 2007. The Non-Hispanic Black population exhibited the fastest increase in mortality among racial/ethnic groups, with an AAPC of 3.20%, whereas Hispanics had the highest AAMR in 2023. The 35-44-year age group showed the fastest increase despite low mortality (AAPC, 3.77%). In 2023, the Midwest had the highest AAMR, at 5.50 per 100,000, followed by the West at 5.32 per 100,000. In standardized urbanization-stratified data through 2020, metropolitan areas had a higher AAMR than nonmetropolitan areas (4.65 vs. 4.30 per 100,000). Subtype-specific analyses showed that intrahepatic cholangiocarcinoma accounted for the largest proportion of deaths (132,830; 58.76%) and had an increasing AAMR from 1.82 to 4.17 per 100,000, whereas gallbladder cancer accounted for 51,720 deaths (22.88%) and had a declining AAMR from 1.46 to 0.98 per 100,000. Extrahepatic bile duct cancer, ampulla of Vater cancer, and other/unspecified BTCs contributed 18,669, 5,135, and 17,702 deaths, respectively, highlighting that pooled BTC estimates may mask divergent subtype patterns. These opposite iCCA and GBC patterns supported separate subtype reporting rather than interpretation of the pooled BTC estimate alone in this study.
Conclusions: BTC mortality among US adults aged ≥ 35 years increased from 1999 to 2023, with demographic, geographic, urbanization-related, and subtype-specific heterogeneity. These findings support subtype-aware surveillance, early detection, and equitable resource allocation.
期刊介绍:
The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.